{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:22:01Z","timestamp":1790832121289,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bcp.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T12:36:59Z","timestamp":1518784619000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics"],"prefix":"10.1016","volume":"153","author":[{"given":"Taha","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Valentovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary O.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.02.020_b0005","series-title":"Federal Regulation of Methadone Treatment","first-page":"1","article-title":"Executive Summary. Institute of Medicine","author":"Rettig","year":"1995"},{"key":"10.1016\/j.bcp.2018.02.020_b0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride","volume":"23","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2018.02.020_b0015","first-page":"347","article-title":"Methadone maintenance treatment (MMT): a review of historical and clinical issues","volume":"67","author":"Joseph","year":"2000","journal-title":"Mt Sinai J. Med."},{"issue":"Suppl. A","key":"10.1016\/j.bcp.2018.02.020_b0020","first-page":"S217","article-title":"Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV","volume":"12","author":"Drucker","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2018.02.020_b0025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2217\/pgs.14.56","article-title":"Pharmacogenomics of methadone maintenance treatment","volume":"15","author":"Somogyi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2018.02.020_b0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ewjm.172.1.43","article-title":"Use of methadone","volume":"172","author":"Anderson","year":"2000","journal-title":"West J. Med."},{"key":"10.1016\/j.bcp.2018.02.020_b0035","first-page":"109","article-title":"Is it time to consider use of levomethadone (R-(-)-methadone) to replace racemic methadone?","volume":"2","author":"Lisberg","year":"2013","journal-title":"J. Develop Drugs"},{"key":"10.1016\/j.bcp.2018.02.020_b0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3109\/10826088109038903","article-title":"Methadone treatment and physical complaints: a clinical analysis","volume":"16","author":"Langrod","year":"1981","journal-title":"Int. J. Addict."},{"key":"10.1016\/j.bcp.2018.02.020_b0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1749-6632.1996.tb15121.x","article-title":"Molecular mechanism of opiate receptor coupling to G proteins and effector systems","volume":"780","author":"Reisine","year":"1996","journal-title":"Ann. New York Acad. Sci."},{"key":"10.1016\/j.bcp.2018.02.020_b0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03256276","article-title":"Interindividual variability of methadone response: impact of genetic polymorphism","volume":"12","author":"Li","year":"2008","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0055","unstructured":"Methadose\u2122 Oral Concentrate (methadone hydrochloride oral concentrate USP) and Methadose\u2122 Sugar-Free Oral Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free, unflavored [package insert]. Mallinckrodt Pharmaceuticals, Inc., Hazelwood, MO, 2016. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/017116s029lbl.pdf. Accessed Nov 3, 2017>."},{"key":"10.1016\/j.bcp.2018.02.020_b0060","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2008.04.007","article-title":"Methadone: a closer look at the controversy","volume":"36","author":"Gaertner","year":"2008","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.bcp.2018.02.020_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10408363.2011.620601","article-title":"Methadone: a review of drug-drug and pathophysiological interactions","volume":"48","author":"Kapur","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.bcp.2018.02.020_b0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1360-0443.2011.03374.x","article-title":"(R)-methadone versus racemic methadone: what is best for patient care?","volume":"106","author":"McCance-Katz","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.bcp.2018.02.020_b0075","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2018.02.020_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: the foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.bcp.2018.02.020_b0085","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1172\/JCI60390","article-title":"Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics","volume":"122","author":"Kreek","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2018.02.020_b0090","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/ADM.0b013e3182a8a4f2","article-title":"Prospective study of QTc changes among former opiate addicts since admission to methadone maintenance treatment: benzodiazepine risk","volume":"7","author":"Peles","year":"2013","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.bcp.2018.02.020_b0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.18773\/austprescr.2013.033","article-title":"Opioid treatment of opioid addiction","volume":"36","author":"McDonough","year":"2013","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.bcp.2018.02.020_b0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1526-4637.2000.00027.x","article-title":"Methadone in the treatment of chronic nonmalignant pain: a 2-year follow-up","volume":"1","author":"Taylor","year":"2000","journal-title":"Pain Med."},{"key":"10.1016\/j.bcp.2018.02.020_b0105","first-page":"1353","article-title":"Methadone treatment for pain states","volume":"71","author":"Toombs","year":"2005","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.bcp.2018.02.020_b0110","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1399-6576.2008.01597.x","article-title":"Clinical pharmacology of methadone for pain","volume":"52","author":"Fredheim","year":"2008","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.bcp.2018.02.020_b0115","first-page":"1155","article-title":"Chronic nonmalignant pain in primary care","volume":"78","author":"Jackman","year":"2008","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.bcp.2018.02.020_b0120","first-page":"1091","article-title":"Opioids for managing chronic non-malignant pain: safe and effective prescribing","volume":"52","author":"Kahan","year":"2006","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.bcp.2018.02.020_b0125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","article-title":"Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths \u2014 United States, 2002\u20132014","volume":"65","author":"Jones","year":"2016","journal-title":"Morb. Mortal Wkly Rep."},{"key":"10.1016\/j.bcp.2018.02.020_b0130","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths \u2014United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"Morb. Mortal Wkly Rep."},{"key":"10.1016\/j.bcp.2018.02.020_b0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2125.2004.02221.x","article-title":"Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure","volume":"58","author":"Mitchell","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.resp.2009.09.001","article-title":"S-Methadone augments R-methadone induced respiratory depression in the neonatal guinea pig","volume":"169","author":"Silverman","year":"2009","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.bcp.2018.02.020_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.12703\/P6-79","article-title":"Opioid-induced respiratory depression: reversal by non-opioiddrugs","volume":"6","author":"van der Schier","year":"2014","journal-title":"F1000Prime Rep."},{"key":"10.1016\/j.bcp.2018.02.020_b0150","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","article-title":"Substitution of (R, S)-methadone by (R)-methadone impact on QT interval","volume":"170","author":"Ansermot","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcp.2018.02.020_b0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","article-title":"Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study","volume":"23","author":"Dobrinas","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bcp.2018.02.020_b0165","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s40262-016-0415-2","article-title":"Population genetic based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients","volume":"55","author":"Csajka","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2018.02.020_b0170","first-page":"1347","article-title":"The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone","volume":"25","author":"Moody","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.02.020_b0175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0022-3565(24)29471-4","article-title":"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation","volume":"298","author":"Oda","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0180","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone\u2013metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.02.020_b0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bcp.2004.04.011","article-title":"Methadone metabolism by human placenta","volume":"68","author":"Nanovskaya","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0190","first-page":"1008","article-title":"Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage?","volume":"12","author":"Lehotay","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bcp.2018.02.020_b0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","article-title":"Pharmacokinetics of methadone","volume":"19","author":"Lugo","year":"2005","journal-title":"J. PainPalliat Care Pharmacother."},{"key":"10.1016\/j.bcp.2018.02.020_b0200","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2018.02.020_b0205","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2174\/1568026043387070","article-title":"Pharmacogenetics of the Cytochromes P450","volume":"4","author":"Daly","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2018.02.020_b0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcp.2018.02.020_b0215","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/03602532.2016.1192642","article-title":"Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response","volume":"48","author":"Dinis-Oliveira","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2018.02.020_b0220","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm00266a009","article-title":"Urinary metabolites of dl-methadone in maintenance subjects","volume":"16","author":"Sullivan","year":"1973","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.02.020_b0225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cpt1975173258","article-title":"Disposition of methadone in methadone maintenance","volume":"17","author":"Angg\u00e5rd","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2018.02.020_b0235","series-title":"Foye's Principles of Medicinal Chemistry","first-page":"686","article-title":"Chapter 20\/Central Analgesics","author":"Lemke","year":"2013"},{"key":"10.1016\/j.bcp.2018.02.020_b0240","first-page":"115","article-title":"Metabolism and disposition of prescription opioids: a review","volume":"27","author":"DePriest","year":"2015","journal-title":"Forensic Sci. Rev."},{"key":"10.1016\/j.bcp.2018.02.020_b0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate","volume":"70","author":"Boulton","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0250","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archpsyc.1997.01830200015002","article-title":"Drug abuse and addiction treatment research. The next generation","volume":"54","author":"Leshner","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2018.02.020_b0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00007691-199606000-00001","article-title":"Stereoselective pharmacokinetics of methadone in chronic pain patients","volume":"18","author":"Kristensen","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2018.02.020_b0260","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1124\/dmd.108.026047","article-title":"A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450","volume":"37","author":"Wang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.02.020_b0265","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2018.02.020_b0270","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0275","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14622416.5.7.895","article-title":"Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population","volume":"5","author":"Solus","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2018.02.020_b0280","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/clpt.2010.314","article-title":"Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy","volume":"89","author":"Sadee","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0285","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000184709","article-title":"CNVs of human genes and their implication in pharmacogenetics","volume":"123","author":"Johansson","year":"2008","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.bcp.2018.02.020_b0290","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/17425255.2012.657626","article-title":"Cytochrome P450 variations in different ethnic populations","volume":"8","author":"McGraw","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2018.02.020_b0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2018.02.020_b0300","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v. 2.0: the next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcp.2018.02.020_b0305","unstructured":"I.F. Fokkema, J.T. den Dunnen, CYP1A2 gene homepage. Available from: <https:\/\/www.LOVD.nl\/\/CYP1A2 2017> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0310","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2018.02.020_b0315","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/dmd.31.6.742","article-title":"Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.02.020_b0320","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12272-014-0348-y","article-title":"Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations","volume":"38","author":"Kim","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bcp.2018.02.020_b0330","unstructured":"A. Daly, CYP2 family [Video file]. In: The Biomedical & Life Sciences Collection, Henry Stewart Talks, 2016. Available from: <https:\/\/hstalks.com\/bs\/685\/> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0335","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0340","unstructured":"I.F. Fokkema, J.T. den Dunnen, CYP2B6 gene homepage. Available from: <https:\/\/www.LOVD.nl\/CYP2B6 2017> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0345","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0350","unstructured":"M. Ingelman-Sundberg, A.K. Daly, D.W. Nebert, CYP2B6 allele nomenclature of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: <https:\/\/www.pharmvar.org\/htdocs\/archive\/index_original.htm> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0355","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2018.02.020_b0360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jat\/bkw135","article-title":"Tell-tale SNPs: the role of CYP2B6 in methadone fatalities","volume":"41","author":"Ahmad","year":"2017","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.bcp.2018.02.020_b0365","doi-asserted-by":"crossref","first-page":"741403","DOI":"10.1155\/2013\/741403","article-title":"Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan","volume":"2013","author":"Lee","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2018.02.020_b0370","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.bcp.2018.02.020_b0375","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bcp.2018.02.020_b0380","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/dmd.115.064352","article-title":"Differences in methadone metabolism by CYP2B6 variants","volume":"43","author":"Gadel","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.02.020_b0385","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0390","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/FTD.0000000000000437","article-title":"Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment","volume":"39","author":"Kringen","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2018.02.020_b0395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/dmd.112.050625","article-title":"Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6","volume":"41","author":"Gadel","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.02.020_b0400","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer","volume":"31","author":"Wang","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0405","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2018.02.020_b0410","doi-asserted-by":"crossref","first-page":"e19527","DOI":"10.1371\/journal.pone.0019527","article-title":"Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response","volume":"6","author":"Fonseca","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.02.020_b0415","unstructured":"I.F. Fokkema, J.T. den Dunnen, CYP2C18 gene homepage, 2017. Available from: <https:\/\/www.LOVD.nl\/\/CYP2C18> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0420","unstructured":"I.F. Fokkema, J.T. den Dunnen, CYP2C8 gene homepage, 2017. Available from: <https:\/\/www.LOVD.nl\/\/CYP2C8> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0425","unstructured":"I.F. Fokkema, J.T. den Dunnen, CYP2C19 gene homepage, 2017. Available from: <https:\/\/www.LOVD.nl\/\/CYP2C19> (accessed 21.11.2017)."},{"key":"10.1016\/j.bcp.2018.02.020_b0430","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/omi.2012.0068","article-title":"Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort","volume":"17","author":"Wang","year":"2013","journal-title":"OMICS"},{"key":"10.1016\/j.bcp.2018.02.020_b0435","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40291-015-0137-4","article-title":"A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study","volume":"19","author":"Carlquist","year":"2015","journal-title":"Mol. Diagn. Ther."},{"issue":"Database issue","key":"10.1016\/j.bcp.2018.02.020_b0440","first-page":"D7","article-title":"Database resources of the National Center for Biotechnology Information","volume":"44","author":"NCBI Resource Coordinators","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2018.02.020_b0445","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00004714-200104000-00016","article-title":"Cytochrome P450 2D6 genotype and methadone steady-state concentrations","volume":"21","author":"Eap","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0450","doi-asserted-by":"crossref","first-page":"425","DOI":"10.36076\/ppj.2014\/17\/425","article-title":"A review of the role of genetic testing in pain medicine","volume":"17","author":"Trescot","year":"2014","journal-title":"Pain Physician"},{"key":"10.1016\/j.bcp.2018.02.020_b0455","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5414\/CPP45410","article-title":"Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone","volume":"45","author":"Coller","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.02.020_b0460","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2018.02.020_b0465","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.02.020_b0470","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1345\/aph.1K539","article-title":"Role of CYP3A5 in abnormal clearance of methadone","volume":"42","author":"De Fazio","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2018.02.020_b0475","doi-asserted-by":"crossref","unstructured":"J. Jurica, A. Sulcova, Determination of Cytochrome P450 Metabolic Activity Using Selective Markers, Topics on Drug Metabolism, in: Dr. James Paxton (Ed.), InTech, 2012. Available from: <https:\/\/www.intechopen.com\/books\/topics-on-drug-metabolism\/determination-of-cytochrome-p450-metabolic-activity-using-selective-markers>. doi: 10.5772\/30236.","DOI":"10.5772\/30236"},{"key":"10.1016\/j.bcp.2018.02.020_b0480","doi-asserted-by":"crossref","unstructured":"V. Tam\u00e1si, A. Falus, Genetic and Epigenetic Factors Affecting Cytochrome P450 Phenotype and Their Clinical Relevance, Topics on Drug Metabolism, in: Dr. James Paxton (Ed.), ISBN: 978-953-51-0099-7, InTech, 2012. Available from: <http:\/\/www.intechopen.com\/books\/topics-on-drug-metabolism\/genetic-and-epigenetic-factors-affecting-cytochrome-p450-phenotype-and-their-clinical-significance>.","DOI":"10.5772\/36451"},{"key":"10.1016\/j.bcp.2018.02.020_b0485","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jat\/bku091","article-title":"Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism","volume":"38","author":"Richards-Waugh","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.bcp.2018.02.020_b0490","doi-asserted-by":"crossref","first-page":"e1005910","DOI":"10.1371\/journal.pgen.1005910","article-title":"Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients","volume":"12","author":"Yang","year":"2016","journal-title":"PLoS Genet."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218300777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218300777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:04:45Z","timestamp":1757768685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218300777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":98,"alternative-id":["S0006295218300777"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.02.020","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}